The world's biggest biotech drugmaker by revenue said it's starting a cycle of several important new product launches — big enough that last year it announced major job reductions and other cost cuts to free up money for the launches.
Pharmaceutical Product Development, (PPD) has completed an expansion of its clinical supplies facility in Athlone, Ireland, that will enable the company to double its packaging warehousing capabilities and quadruple its distribution services. Those increases are the result of PPD more than tripling the size of the facility as part of its long-term strategy to expand its global depot network.
The single use bioreactors (SUBs) market is expected to grow at a double digit CAGR of 18.4% to reach $470.9 million by 2019 from $202.5 million in 2014. Developing markets such as China and India are lucrative markets for single-use bioreactors (SUB), owing to the low cost benefits offered by these nations.
The U.S. surgeon general says officials are "in desperate need of clarity" on electronic cigarettes to help guide public health policies.
Governments and private donors, among them the Bill and Melinda Gates Foundation, have pledged a record $7.5 billion to replenish a global vaccination program for the poor.
The Cincinnati company, which sells products ranging from Tide detergent to Crest toothpaste, said Tuesday that exchange rates will remain a challenge well into fiscal 2015, especially in the second half of its year. Overall, it expects foreign exchange to chop its core, fiscal 2015 earnings by 12 percent and reduce its revenue by 5 percent.
Pfizer's fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research spending and legal costs also hurt the bottom line. The world's second-biggest drugmaker by revenue reported lower sales for most of its huge portfolio of prescription medicines, with the biggest hit coming from new generic competition to popular painkiller Celebrex.
Your input is important as BioPlan Associates, Inc., benchmarks global and regional trends affecting our industry. You will receive a FREE summary of the results of this important global study; our 159 Key Industry Facts White Paper; AND for each completed survey BioPlan will donate $10 (up to $10,000) to global health charities.
Pfizer on Tuesday reported fourth-quarter earnings of $1.23B. On a per-share basis, the company said it had net income of 19 cents. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to 54 cents per share.
U.S. Food and Drug Administration Commissioner Margaret A. Hamburg, M.D., has appointed Robert Califf, M.D., a recognized global leader in cardiology, clinical research, and medical economics, as FDA Deputy Commissioner for Medical Products and Tobacco.
The new framework is part of a larger reorganization that VA leaders say will bring a singular focus on customer service to an agency that serves 22 million veterans, including more than 6 million who receive health care each year from the VA's 970 hospitals or clinics.
Teva Pharmaceutical has announced the Food and Drug Administration (FDA) approval of the first generic equivalent to Nexium (esomeprazole magnesium) Delayed-Release Capsules in the United States.
About 10 percent of young leukemia patients of East Asian ancestry inherit a gene variation that is associated with reduced tolerance of a drug that is indispensable for curing acute lymphoblastic leukemia (ALL), the most common childhood cancer.
Novartis AG says fourth quarter net income dropped 26 percent but the company still posted a healthy 2014 annual profit. The Basel, Switzerland-based company said Tuesday that fourth quarter net income came in at $1.49 billion, down from $2 billion in the same quarter the year before.
The Obama administration has announced a plan to shift Medicare payments it makes to hospitals and doctors so they reward quality over volume. Officials said they hoped the move would be a catalyst for the entire health-care system.